A Multicenter, Three Arm, Randomized, Open Label Clinical Study to Compare Renal Function in Liver Transplant Recipients Receiving an Immunosuppressive Regimen of Advagraf (Immediately or Delayed Post-transplant) and MMF With or Without a Monoclonal Anti-IL2R Antibody (Basiliximab).

Trial Profile

A Multicenter, Three Arm, Randomized, Open Label Clinical Study to Compare Renal Function in Liver Transplant Recipients Receiving an Immunosuppressive Regimen of Advagraf (Immediately or Delayed Post-transplant) and MMF With or Without a Monoclonal Anti-IL2R Antibody (Basiliximab).

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Sep 2014

At a glance

  • Drugs Tacrolimus (Primary) ; Basiliximab; Corticosteroids; Mycophenolate mofetil
  • Indications Liver transplant rejection
  • Focus Registrational; Therapeutic Use
  • Acronyms DIAMOND; DIAMOND FRANCE
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Sep 2013 Initial results presented at a late-breaking session at the 16th Congress of the European Society for Organ Transplantation.
    • 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top